Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia

Keyphrases

• Long-term Safety 100%
• Atorvastatin 100%
• Mixed Hyperlipidemia 100%
• Gemfibrozil 100%
• Creatinine Kinase 60%
• Low-density Lipoprotein Cholesterol (LDL-C) 40%
• Daily Dose 40%
• Liver Function Tests 40%
• High-density Lipoprotein Cholesterol (HDL-C) 20%
• Cholesterol 20%
• Creatinine 20%
• Combination Therapy 20%
• Long-term Efficacy 20%
• Plasma Lipids 20%
• Triglycerides 20%
• Myopathy 20%
• Potential Risk 20%
• Other-report 20%
• HMG-CoA Reductase Inhibitors 20%
• Previously Untreated Patients 20%
• Repeated Testing 20%
• Low-density Lipoprotein Triglyceride 20%
• Fibric Acid Derivatives 20%
• Myalgia 20%
• Upper Normal Limit 20%
• Effective Reduction 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Hyperlipidemia 100%
• Pravastatin 100%
• Gemfibrozil 100%
• Creatine Kinase 60%
• Triacylglycerol 40%
• Low Density Lipoprotein Cholesterol 40%
• High Density Lipoprotein Cholesterol 20%
• Creatinine 20%
• Combination Therapy 20%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 20%
• Fibric Acid Derivative 20%
• Myopathy 20%
• Myalgia 20%